Literature DB >> 11104672

In vitro-selected RNA cleaving DNA enzymes from a combinatorial library are potent inhibitors of HIV-1 gene expression.

B Sriram1, A C Banerjea.   

Abstract

Selective inactivation of a target gene by antisense mechanisms is an important biological tool to delineate specific functions of the gene product. Approaches mediated by ribozymes and RNA-cleaving DNA enzymes (DNA enzymes) are more attractive because of their ability to catalytically cleave the target RNA. DNA enzymes have recently gained a lot of importance because they are short DNA molecules with simple structures that are expected to be stable to the nucleases present inside a mammalian cell. We have designed a strategy to identify accessible cleavage sites in HIV-1 gag RNA from a pool of random DNA enzymes, and for isolation of DNA enzymes. A pool of random sequences (all 29 nucleotides long) that contained the earlier-identified 10-23 catalytic motif were tested for their ability to cleave the target RNA. When the pool of random DNA enzymes was targeted to cleave between any A and U nucleotides, DNA enzyme 1836 was identified. Although several DNA enzymes were identified using a pool of DNA enzymes that was completely randomized with respect to its substrate-binding properties, DNA enzyme-1810 was selected for further characterization. Both DNA enzymes showed target-specific cleavage activities in the presence of Mg(2+) only. When introduced into a mammalian cell, they showed interference with HIV-1-specific gene expression. This strategy could be applied for the selection of desired target sites in any target RNA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104672      PMCID: PMC1221503     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  12 in total

1.  Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).

Authors:  Y Wu; L Yu; R McMahon; J J Rossi; S J Forman; D S Snyder
Journal:  Hum Gene Ther       Date:  1999-11-20       Impact factor: 5.695

2.  Targeted cleavage of HIV-1 coreceptor-CXCR-4 by RNA-cleaving DNA-enzyme: inhibition of coreceptor function.

Authors:  S Basu; B Sriram; R Goila; A C Banerjea
Journal:  Antiviral Res       Date:  2000-05       Impact factor: 5.970

3.  Targeted cleavage of HIV-1 envelope gene by a DNA enzyme and inhibition of HIV-1 envelope-CD4 mediated cell fusion.

Authors:  B C Dash; T A Harikrishnan; R Goila; S Shahi; H Unwalla; S Husain; A C Banerjea
Journal:  FEBS Lett       Date:  1998-07-24       Impact factor: 4.124

4.  A general purpose RNA-cleaving DNA enzyme.

Authors:  S W Santoro; G F Joyce
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

5.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

6.  Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis.

Authors:  S Y Paik; A Banerjea; C J Chen; Z Ye; G G Harmison; M Schubert
Journal:  Hum Gene Ther       Date:  1997-06-10       Impact factor: 5.695

7.  New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury.

Authors:  F S Santiago; H C Lowe; M M Kavurma; C N Chesterman; A Baker; D G Atkins; L M Khachigian
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

8.  Reovirus protein sigma 1 translated in vitro, as well as truncated derivatives of it that lack up to two-thirds of its C-terminal portion, exists as two major tetrameric molecular species that differ in electrophoretic mobility.

Authors:  A C Banerjea; W K Joklik
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

9.  First report of a healthy Indian heterozygous for delta 32 mutant of HIV-1 co-receptor-CCR5 gene.

Authors:  S Husain; R Goila; S Shahi; A Banerjea
Journal:  Gene       Date:  1998-01-30       Impact factor: 3.688

10.  Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme.

Authors:  X Zhang; Y Xu; H Ling; T Hattori
Journal:  FEBS Lett       Date:  1999-09-17       Impact factor: 4.124

View more
  9 in total

1.  Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/Rev RNA.

Authors:  H Unwalla; A C Banerjea
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

2.  The role of mPer1 in morphine dependence in mice.

Authors:  Y Liu; Y Wang; C Wan; W Zhou; T Peng; Y Liu; Z Wang; G Li; G Cornelisson; F Halberg
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  EBV-LMP1-targeted DNAzyme restrains nasopharyngeal carcinoma growth in a mouse C666-1 xenograft model.

Authors:  Xia Ke; Yu-cheng Yang; Su-ling Hong
Journal:  Med Oncol       Date:  2010-09-24       Impact factor: 3.064

Review 4.  In vitro selection, characterization, and application of deoxyribozymes that cleave RNA.

Authors:  Scott K Silverman
Journal:  Nucleic Acids Res       Date:  2005-11-11       Impact factor: 16.971

Review 5.  Theranostic DNAzymes.

Authors:  Wenhu Zhou; Jinsong Ding; Juewen Liu
Journal:  Theranostics       Date:  2017-02-23       Impact factor: 11.556

Review 6.  In vitro and ex vivo selection procedures for identifying potentially therapeutic DNA and RNA molecules.

Authors:  Soledad Marton; José A Reyes-Darias; Francisco J Sánchez-Luque; Cristina Romero-López; Alfredo Berzal-Herranz
Journal:  Molecules       Date:  2010-06-28       Impact factor: 4.411

7.  Systematic analysis of the role of target site accessibility in the activity of DNA enzymes.

Authors:  Graeme Doran; Muhammad Sohail
Journal:  J RNAi Gene Silencing       Date:  2006-07-28

8.  Design of efficient DNAzymes against muscle AChR alpha-subunit cRNA in vitro and in HEK 293 cells.

Authors:  Amr Abdelgany; M Khabir Uddin; Matthew Wood; Kazunari Taira; David Beeson
Journal:  J RNAi Gene Silencing       Date:  2005-10-14

9.  RPS2: a novel therapeutic target in prostate cancer.

Authors:  Min Wang; Youji Hu; Mark E Stearns
Journal:  J Exp Clin Cancer Res       Date:  2009-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.